Last checked at 15 Aug 2017 07:00
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 15 August 2017: Shield Therapeutics (LSE: STX), a specialty pharmaceutical company focused on secondary care, announces it will report its interim results for the six months ended 30 June 2017 on Wednesday 20 September 2017.
Shield will host a presentation and conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.
- Ends -
For further information please contact:
Shield Therapeutics plc | +44 (0)20 7186 8500 | |
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer Karl Keegan, Director Corporate Development | ||
Nominated Adviser and Joint Broker |
+44 (0)20 3100 2222 | |
Liberum Capital Limited | ||
Christopher Britton Steve Pearce Jonathan Wilkes-Green | ||
Joint Broker | +44 (0)20 7418 8900 | |
Peel Hunt LLP | ||
James Steel Alastair Rae | ||
Oliver Jackson | ||
Financial PR Advisor | +44 (0) 203 709 5700 | |
Consilium Strategic Communications | ||
Mary-Jane Elliott Matthew Neal | ||
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com